Evaluation of direct medical and non-medical costs of Unfractionated Heparin and Low Molecular Weight Heparin in Hospitalized Patients with Stroke due to Atrial Fibrillation

Subject Areas : medical documents

Jamshid Bahmei ¹ , nahid Hatam ² , afshin Borhani Haghighi ³ , farnia Feiz ⁴ , reihane Sedghi ⁵ , Khosro Keshavarz ⁶

1 - MSc in Health Care Services Management, School of Management and Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran
2 - Professor of Health Care Services Management, School of Management and Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran
3 - Associate professor of Neurology, Department of Neurology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
4 - MD, Clinical Neurology Research Center, Shiraz University of Medical Science, Shiraz, Iran
5 - MD, Clinical Neurology Research Center, Shiraz University of Medical Science, Shiraz, Iran
6 - Assistant Professor in Health Economics, Department of Health Economics, School of Management and Medical Informatics, Shiraz University of Medical Science, Shiraz, Iran

Received: 2015-10-17 Accepted : 2016-02-10 Published : 2016-02-20

Keywords: Price, Heparin, Stroke, Clexane,

Abstract :

Introduction: Diagnosis and treatment of patients with stroke spent high expenses annually. The aim of this study is to evaluate the direct medical and non-medical costs of stroke patients of Nemazee hospital. Methods: This study is a descriptive, cross-sectional analysis that from April to July 2015 Namazi Hospital in Shiraz. The study population in this studies all patients with stroke in atrial fibrillation patients who have been treated with drugs or heparin clexan. The sample size was 80 and data were collected by questionnaire form and through interview. sampling was stratified sampling. Data were analyzed with using SPSS 18 software and descriptive statistics, t-test and one-way ANOVA test. Results: Average direct medical costs, direct non-medical costsand indirects costs of unfractionated heparinwere: 27,340,000±10,010,000 Rials, 3,862,750 ± 2,851,490 Rials and 5,382,500 ± 4,934,950 Rials respectively. Same averagedirect medical costs, direct non-medical costsand indirects costs of low molecular weight heparin were: 24,664,250±14,649,890 Rials, 2,233,500±4,249,590 Rials and 2,572,500±2,625,310 Rials respectively. Conclusion: Clexane drug compared to heparin treatment option with less total cost on the prevention of stroke in patients. The results of this study can also help patients to specialists and neurologists who can clexane of drug use in the treatment of lower cost. Introduction: Diagnosis and treatment of patients with stroke spent high expenses annually. The aim of this study is to evaluate the direct medical and non-medical costs of stroke patients of Nemazee hospital.Methods: This study was a descriptive-analytic study that was done cross- sectional in Shiraz hospital Nemazee in 2015. Research society for study included all of hospitalized stroke patients due to atrial fibrillation, which were treated with unfractionated heparin and low molecular weight heparin. The sample size was 80 and data were collected by questionnaire form and through interview. Sampling was stratified sampling. Data were analyzed with using SPSS 18 software and descriptive statistics, t-test and one-way ANOVA test.Results: Mean direct medical costs, direct non-medical costs and indirects costs of unfractionated heparin were: 27,340,000±10,010,000 Rials, 3,862,750 ± 2,851,490 Rials and 5,382,500 ± 4,934,950 Rials respectively. Also mean direct medical costs, direct non-medical costs and indirects costs of low molecular weight heparin were: 24,664,250±14,649,890 Rials, 2,233,500±4,249,590 Rials and 2,572,500±2,625,310 Rials respectively.Conclusion: costs less than unfractionated heparin for the prevention of stroke in patients. So the results of this research can be remarked as a case study to proof lower costs of low molecular weight heparin for patients treatment and help neurology specialists to select the more acurate drug to decrease treatment costs.